| 名稱(chēng) | Vemurafenib |
| 描述 | Vemurafenib (RG7204) is a B-RAF inhibitor that inhibits RAFV600E and c-RAF-1 (IC50=31/48 nM) selectively and potently. Vemurafenib exhibits antitumor activity and is used for the treatment of BRAF V600E mutation-positive melanoma. |
| 細(xì)胞實(shí)驗(yàn) | Cellular proliferation was evaluated by MTT assay. Briefly, cells were plated in 96-well microtiter plates at a density of 1,000 to 5,000 cells per well in a volume of 180 μL. For the assay, RG7204 was prepared at 10 times the final assay concentration in media containing 1% DMSO. Twenty-four hours after cell plating, 20 μL of the appropriate dilution were added to plates in duplicate. The plates were assayed for proliferation 6 days after the cells were plated according to the procedure originally described by Mosmann [2]. |
| 激酶實(shí)驗(yàn) | Expression and purification of B-RAF, structure determination, and protein kinase activity measurements were carried out as previously described. To obtain co-crystals of B-RAFV600E with PLX4032, the protein solution was initially mixed with the compound dissolved in DMSO at a final compound concentration of 1 mM. This complex was co-crystallized by a sitting drop vapor diffusion experiment in which equal volumes of complex (at 10 mg/ml concentration) and reservoir solution (100mM BisTris at pH 6.0, 12.5% 2,5-hexanediol, and 12% PEG3350) were mixed and allowed to equilibrate against the reservoir at 4°C. The crystal was soaked in cryosolvent, followed by flash-freezing in liquid nitrogen. The data were collected at Beamline ALS831 with the wavelength of 1.11?. The Ramachandran plot from the refined structure shows that 94%, 5.6% and 0.4% residues are in the most favored, additional allowed and generously allowed regions, respectively. A summary of the crystallography statistics is included in Supplementary Table 3. COLO205 tumor xenograft studies (Molecular Imaging Research, Ann Arbor, MI) were carried out as previously described either using a conventional formulation (5%DMSO, 1% methylcellulose) or using the MBP formulation [1]. |
| 動(dòng)物實(shí)驗(yàn) | All animal procedures were approved by the Ethical Commission of the Institute for Cancer Research and Treatment and by the Italian Ministry of Health. WiDr cells were injected subcutaneously into the right posterior flanks of 7-week-old immunodeficient NODSCID female mice (6 mice per group). Tumour formation was monitored twice a week, and tumour volume based on caliper measurements was calculated by the modified ellipsoidal formula: tumour volume = 1/2 length × width. When tumours reached a volume of approximately 200–250 mm^3, mice were randomly assigned to treatment with vehicle or drug(s) [3]. |
| 體外活性 | 方法：黑色素瘤細(xì)胞 A375 和 SK-Mel-28 用 Vemurafenib (0-8 μM) 處理 48 h，使用 CCK-8 assay 檢測(cè)細(xì)胞活力。
結(jié)果：Vemurafenib 劑量依賴(lài)性抑制 A375 和 SK-Mel-28 細(xì)胞增殖，IC50 分別為 0.8 μM 和 1.8 μM。[1]
方法：表達(dá) BRAF V600E 的黑色素瘤細(xì)胞系 Colo829 和 LOX 用 Vemurafenib (0.05-30 μmol/L) 處理 2 h，使用 Western Blot 方法檢測(cè)靶點(diǎn)蛋白表達(dá)水平。
結(jié)果：Vemurafenib 抑制了 Colo829 和 LOX 細(xì)胞中 MEK 和 ERK 的磷酸化。[2] |
| 體內(nèi)活性 | 方法：為檢測(cè)體內(nèi)抗腫瘤活性，將 Vemurafenib (12.5-75 mg/kg，suspended in an aqueous vehicle containing 2% Klucel LF and adjusted to pH 4 with dilute HCl.) 口服給藥給攜帶黑色素瘤 LOX 的 Athymic nude 小鼠，每天兩次，持續(xù) 11-13 天。
結(jié)果：Vemurafenib 顯著抑制腫瘤生長(zhǎng)并誘導(dǎo)腫瘤消退。[2]
方法：為檢測(cè)體內(nèi)抗腫瘤活性，將 Vemurafenib (60 mg/kg) 口服給藥給攜帶黑色素瘤 Colo-205 的 athymic mice 小鼠，每天兩次，持續(xù)十四天。
結(jié)果：Vemurafenib 有效抑制 Colo-205 異種移植小鼠模型中的腫瘤生長(zhǎng)。[3] |
| 存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 9 mg/mL (18.37 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 18.33 mg/mL (37.42 mM), Sonication is recommended.
|
| 關(guān)鍵字 | Raf kinases | PLX 4032 | inhibit | RG 7204 | PLX-4032 | Inhibitor | RO-5185426 | Vemurafenib | Raf | RG-7204 | Autophagy | RO 5185426 | 1029872-54-5 |
| 相關(guān)產(chǎn)品 | Guanidine hydrochloride | Naringin | Valproic Acid | Taurine | Gefitinib | Aceglutamide | Hydroxychloroquine | Curcumin | Stavudine | Salicylic acid | Paeonol | Sodium 4-phenylbutyrate |
| 相關(guān)庫(kù) | 抑制劑庫(kù) | 抗癌上市藥物庫(kù) | 經(jīng)典已知活性庫(kù) | EMA 上市藥物庫(kù) | 激酶抑制劑庫(kù) | 抗衰老化合物庫(kù) | 酪氨酸激酶分子庫(kù) | 藥物功能重定位化合物庫(kù) | 抗癌臨床化合物庫(kù) | 抗癌藥物庫(kù) |